Profiling formalin-fixed, paraffin-embedded (FFPE) samples on three Agilent microarray platforms
Poster Aug 20, 2009
Thousands of formalin-fixed, paraffin-embedded (FFPE) samples from clinical archives are available for retrospective studies. Such samples could provide crucial information for drug target discovery and diagnostics of various diseases. Here we used FFPE samples and their matched fresh-frozen (FF) counterparts to examine their performance on three types of microarrays including whole genome expression, comparative genomic hybridization (CGH) and microRNA.
Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy TargetsPoster
The human immune system is comprised of a complex network of immune checkpoint receptors that are promising new immunotherapy targets for the treatment of a variety of diseases including cancer and autoimmune-mediated disorders.READ MORE
Applications of chemically modified synthetic guide RNA for CRISPR-Cas9 genome editingPoster
Our results indicate that MS modifications are required for experiments with co-electroporation of Cas9 mRNA and synthetic gRNA, yet have no impact on editing efficiency when delivered with lipid-based transfection reagents.READ MORE
Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell LinesPoster
Inecalcitol is a vitamin D receptor agonist currently in Phase II clinical trial in AML (acute myeloid leukemia). Inecalcitol increases the expression of CD38 at the surface of 5 multiple myeloma cell lines; therefore, inecalcitol could potentiate the clinical response of MM patients to a therapeutic anti-CD38 antibody
Inecalcitol induces the expression of the CD38 antigen at the surface of 4 AML cell lines; thus, inecalcitol could render AML patients sensitive to a therapeutic anti-CD38.